Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.44 |
| ▸ | EGFR | P00533 | 12/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928280 | 0.92 | EGFR (0.54) | ERBB2EGFRKDRLCK | |
| SCHEMBL9928315 | 0.91 | EGFR (0.53) | ERBB2EGFRKDRLCK | |
| SCHEMBL9928282 | 0.87 | EGFR (0.53) | ERBB2EGFRBRAFTNNI3K | |
| SCHEMBL9928289 | 0.85 | AXL (0.39) | ERBB2EGFRKDREPHA2DRD2 | |
| SCHEMBL9928291 | 0.83 | EGFR (0.53) | ERBB2EGFRKDRBRAFTNNI3K | |
| SCHEMBL9928303 | 0.83 | TTBK1 (0.45) | ERBB2EGFRKDRDRD4DRD3 | |
| SCHEMBL9928279 | 0.83 | LRRK2 (0.39) | ERBB2EGFRDRD2DRD4DRD3 | |
| SCHEMBL9904005 | 0.83 | EGFR (0.65) | ERBB2EGFRKDRLCK | |
| SCHEMBL9897094 | 0.82 | AAK1 (0.51) | ERBB2EGFRKDREPHA2EPHB4 | |
| SCHEMBL9928290 | 0.82 | MERTK (0.39) | ERBB2EGFRKDRLCKDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | ERBB2 1/4885EGFR 2/4885KDR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.